Medigene Ag (MDGEF) 7.8600 $MDGEF
Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq8dm9/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Basal Cell Carcinoma Basal Cell Epithelioma Overview - Therapeutics Development - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Overview - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Comparative Analysis - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biosceptre (Aust) Pty Ltd - Genextra S.p.a. - Ignyta, Inc. - Laboratories Ojer Pharma S.L. - MediGene AG - Novartis AG - Redx Pharma Plc - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Transgene SA For more information visit http://www.researchandmarkets.com/research/hq8dm9/basal_cell
RXDX: 5.51 (+0.01), NVS: 83.26 (+1.18)
Global Genital Warts (Condylomata Acuminata) Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ppm8zf/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Genital Warts (Condylomata Acuminata) Overview - Therapeutics Development - Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview - Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis - Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies - Genital Warts (Condylomata Acuminata) - Therapeutics under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Genital Warts (Condylomata Acuminata) - Products under Development by Companies - Genital Warts (Condylomata Acuminata) - Products under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - Laboratories Ojer Pharma S.L. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Novartis AG - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/pp...ital_warts
BOTA: 1.55 (-0.04), FOMX: 8.52 (+0.35), NNVC: 1.75 (-0.02), NVS: 83.26 (+1.18)
Global Primary Biliary Cirrhosis Pipeline Review, H2 2015 - 10 Companies & 11 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvgssb/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - CymaBay Therapeutics, Inc. - Dr. Falk Pharma GmbH - Enanta Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - MBX-8025 - NGM-282 - obeticholic acid - RhuDex - Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/xv...ry_biliary
JNJ: 125.23 (+0.77), ICPT: 173.03 (+6.13), CBAY: 1.89 (+0.04), VBAY: (), GSK: 45.07 (-0.11), ENTA: 22.49 (+1.49)
Global Germ Cell Tumors Pipeline Review H2 2015 - 8 Companies & 11 Drug Profiles
M2 - Mon Oct 05, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/444kf4/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - ArQule, Inc. - Astex Pharmaceuticals, Inc. - GlaxoSmithKline Plc - MediGene AG - Merck & Co., Inc. - Novartis AG - Philogen S.p.A. - Sanofi Drug Profiles - cabazitaxel - Cell Therapy 1 for Oncology - (dabrafenib mesylate trametinib dimethyl sulfoxide) - G-207 - guadecitabine - pembrolizumab - ribociclib - Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Small Molecules to Inhibit Tubulin for Oncology - Tetravil - tivantinib For more information visit http://www.researchandmarkets.com/research/44...ell_tumors
MRK: 58.66 (+0.23), ARQL: 1.66 (+0.03), GSK: 45.07 (-0.11), NVS: 83.26 (+1.18)
Global Warts Pipeline Review 2015 - 19 Companies & 24 Drug Profiles
M2 - Tue Sep 08, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xj7l6/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - EpiPharm AG - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Nielsen Biosciences, Inc. - Novan, Inc. - Novartis AG - Promius Pharma, LLC - RXi Pharmaceuticals Corporation - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (digoxin furosemide) - 854-A - A-101 - AP-611074 - AS-101 - AX-03 - Candida Albicans Antigen - DFD-05 - diphencyprone - EPI-N06 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - LFX-453 - NVN-1000 - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 - Vaccine for Cervical Cancer and Genital Warts For more information visit http://www.researchandmarkets.com/research/9x...s_pipeline
BOTA: 1.55 (-0.04), FOMX: 8.52 (+0.35), NNVC: 1.75 (-0.02), NVS: 83.26 (+1.18)
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 4.86 (+0.04), PFE: 36.89 (+0.22), AZN: 34.14 (-0.15), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), STML: 7.40 (-0.05)
Global Genital Warts (Condylomata Acuminata) Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 11:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dg4t8/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015" report to their offering. Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata Acuminata). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Warts (Condylomata Acuminata). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Genital Warts (Condylomata Acuminata) Therapeutics Clinical Trials - Merck & Co., Inc. - BioMAS Ltd. - Valeant Pharmaceuticals International, Inc. - MediGene AG - Gilead Sciences, Inc. - G&E Herbal Biotechnology Co., Ltd. - Biota Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Clinical Trial Overview of Top Institutes / Government - China Medical University - Department of Biotechnology, India - Deutsches Krebsforschungszentrum - Duke University - Huazhong University of Science & Technology - Johannes Gutenberg University Mainz - Kenyatta National Hospital - Medical University of Vienna - Mount Sinai Medical Center - National Cheng-Kung University Hospital For more information visit http://www.researchandmarkets.com/research/5d...ital_warts
GILD: 79.47 (-1.77), BOTA: 1.55 (-0.04), MRK: 58.66 (+0.23), VRX.TO: 29.08 (-1.37)
Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H1 2015 - 8 Companies & 8 Drug Profiles
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brrxqg/vaginal_atrophy) has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - EndoCeutics, Inc. - Foamix Pharmaceuticals Ltd. - MediGene AG - Pantarhei Bioscience BV - Peptonic medical AB - RestorGenex Corporation - TherapeuticsMD Inc. Drug Profiles - esterol - estradiol hemihydrate - oxytocin - prasterone - RES-102 - sinecatechins - TX-004HR - WC-3011 For more information visit http://www.researchandmarkets.com/research/br...al_atrophy
TXMD: 7.77 (+0.04), FOMX: 8.52 (+0.35)
Genital Warts (Condylomata Acuminata) Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Wed Jun 24, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tcqv8c/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agilvax, Inc. - Anaconda Pharma - Biogenomics Limited - BioMAS Ltd. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Tamir Biotechnology, Inc. Drug Profiles - AP-611074 - AS-101 - AX-03 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 For more information visit http://www.researchandmarkets.com/research/tc...ital_warts
FOMX: 8.52 (+0.35), NNVC: 1.75 (-0.02)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15), STML: 7.40 (-0.05), CELGZ: 1.16 (-0.01)
Global Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development Pipeline Review, H1 2015 - 16 Drug Profiles & 11 Companies
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnpg9f/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biogenomics Limited - Biosceptre International Limited - Bristol-Myers Squibb Company - Genextra S.p.a. - MediGene AG - Novartis AG - Oncovir, Inc. - Redx Pharma Ltd - Transgene SA Drug Profiles - aminolevulinic acid hydrochloride - BIL-010t - BMS-833923 - CIGB-128 - CS-S/BCC-1 - CS-TATI-1 - DAC-060 - erismodegib - interferon alfa-2b (recombinant) - LEQ-506 - Oshadi D Oshadi R - Poly-ICLC - sinecatechins - Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma - Small Molecules to Inhibit Casein Kinase 1 for Cancer - TG-1042 For more information visit http://www.researchandmarkets.com/research/wnpg9f/basal_cell
BMY: 74.81 (+0.15), NVS: 83.26 (+1.18)
Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), ICPT: 173.03 (+6.13), VBAY: (), GSK: 45.07 (-0.11)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 5.80 (+0.19), INO: 9.88 (+0.26), ADXS: 8.34 (+0.16), GSK: 45.07 (-0.11), NKTR: 17.29 (+1.19), NVS: 83.26 (+1.18)
Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq8dm9/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Basal Cell Carcinoma Basal Cell Epithelioma Overview - Therapeutics Development - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Overview - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Comparative Analysis - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biosceptre (Aust) Pty Ltd - Genextra S.p.a. - Ignyta, Inc. - Laboratories Ojer Pharma S.L. - MediGene AG - Novartis AG - Redx Pharma Plc - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Transgene SA For more information visit http://www.researchandmarkets.com/research/hq8dm9/basal_cell
RXDX: 5.51 (+0.01), NVS: 83.26 (+1.18)
Global Genital Warts (Condylomata Acuminata) Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ppm8zf/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Genital Warts (Condylomata Acuminata) Overview - Therapeutics Development - Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview - Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis - Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies - Genital Warts (Condylomata Acuminata) - Therapeutics under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Genital Warts (Condylomata Acuminata) - Products under Development by Companies - Genital Warts (Condylomata Acuminata) - Products under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - Laboratories Ojer Pharma S.L. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Novartis AG - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/pp...ital_warts
BOTA: 1.55 (-0.04), FOMX: 8.52 (+0.35), NNVC: 1.75 (-0.02), NVS: 83.26 (+1.18)
Global Primary Biliary Cirrhosis Pipeline Review, H2 2015 - 10 Companies & 11 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvgssb/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - CymaBay Therapeutics, Inc. - Dr. Falk Pharma GmbH - Enanta Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - MBX-8025 - NGM-282 - obeticholic acid - RhuDex - Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/xv...ry_biliary
JNJ: 125.23 (+0.77), ICPT: 173.03 (+6.13), CBAY: 1.89 (+0.04), VBAY: (), GSK: 45.07 (-0.11), ENTA: 22.49 (+1.49)
Global Germ Cell Tumors Pipeline Review H2 2015 - 8 Companies & 11 Drug Profiles
M2 - Mon Oct 05, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/444kf4/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - ArQule, Inc. - Astex Pharmaceuticals, Inc. - GlaxoSmithKline Plc - MediGene AG - Merck & Co., Inc. - Novartis AG - Philogen S.p.A. - Sanofi Drug Profiles - cabazitaxel - Cell Therapy 1 for Oncology - (dabrafenib mesylate trametinib dimethyl sulfoxide) - G-207 - guadecitabine - pembrolizumab - ribociclib - Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Small Molecules to Inhibit Tubulin for Oncology - Tetravil - tivantinib For more information visit http://www.researchandmarkets.com/research/44...ell_tumors
MRK: 58.66 (+0.23), ARQL: 1.66 (+0.03), GSK: 45.07 (-0.11), NVS: 83.26 (+1.18)
Global Warts Pipeline Review 2015 - 19 Companies & 24 Drug Profiles
M2 - Tue Sep 08, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xj7l6/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - EpiPharm AG - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Nielsen Biosciences, Inc. - Novan, Inc. - Novartis AG - Promius Pharma, LLC - RXi Pharmaceuticals Corporation - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (digoxin furosemide) - 854-A - A-101 - AP-611074 - AS-101 - AX-03 - Candida Albicans Antigen - DFD-05 - diphencyprone - EPI-N06 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - LFX-453 - NVN-1000 - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 - Vaccine for Cervical Cancer and Genital Warts For more information visit http://www.researchandmarkets.com/research/9x...s_pipeline
BOTA: 1.55 (-0.04), FOMX: 8.52 (+0.35), NNVC: 1.75 (-0.02), NVS: 83.26 (+1.18)
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 4.86 (+0.04), PFE: 36.89 (+0.22), AZN: 34.14 (-0.15), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), STML: 7.40 (-0.05)
Global Genital Warts (Condylomata Acuminata) Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 11:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dg4t8/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015" report to their offering. Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata Acuminata). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Warts (Condylomata Acuminata). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Genital Warts (Condylomata Acuminata) Therapeutics Clinical Trials - Merck & Co., Inc. - BioMAS Ltd. - Valeant Pharmaceuticals International, Inc. - MediGene AG - Gilead Sciences, Inc. - G&E Herbal Biotechnology Co., Ltd. - Biota Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Clinical Trial Overview of Top Institutes / Government - China Medical University - Department of Biotechnology, India - Deutsches Krebsforschungszentrum - Duke University - Huazhong University of Science & Technology - Johannes Gutenberg University Mainz - Kenyatta National Hospital - Medical University of Vienna - Mount Sinai Medical Center - National Cheng-Kung University Hospital For more information visit http://www.researchandmarkets.com/research/5d...ital_warts
GILD: 79.47 (-1.77), BOTA: 1.55 (-0.04), MRK: 58.66 (+0.23), VRX.TO: 29.08 (-1.37)
Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H1 2015 - 8 Companies & 8 Drug Profiles
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brrxqg/vaginal_atrophy) has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - EndoCeutics, Inc. - Foamix Pharmaceuticals Ltd. - MediGene AG - Pantarhei Bioscience BV - Peptonic medical AB - RestorGenex Corporation - TherapeuticsMD Inc. Drug Profiles - esterol - estradiol hemihydrate - oxytocin - prasterone - RES-102 - sinecatechins - TX-004HR - WC-3011 For more information visit http://www.researchandmarkets.com/research/br...al_atrophy
TXMD: 7.77 (+0.04), FOMX: 8.52 (+0.35)
Genital Warts (Condylomata Acuminata) Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Wed Jun 24, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tcqv8c/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agilvax, Inc. - Anaconda Pharma - Biogenomics Limited - BioMAS Ltd. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Tamir Biotechnology, Inc. Drug Profiles - AP-611074 - AS-101 - AX-03 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 For more information visit http://www.researchandmarkets.com/research/tc...ital_warts
FOMX: 8.52 (+0.35), NNVC: 1.75 (-0.02)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15), STML: 7.40 (-0.05), CELGZ: 1.16 (-0.01)
Global Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development Pipeline Review, H1 2015 - 16 Drug Profiles & 11 Companies
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnpg9f/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biogenomics Limited - Biosceptre International Limited - Bristol-Myers Squibb Company - Genextra S.p.a. - MediGene AG - Novartis AG - Oncovir, Inc. - Redx Pharma Ltd - Transgene SA Drug Profiles - aminolevulinic acid hydrochloride - BIL-010t - BMS-833923 - CIGB-128 - CS-S/BCC-1 - CS-TATI-1 - DAC-060 - erismodegib - interferon alfa-2b (recombinant) - LEQ-506 - Oshadi D Oshadi R - Poly-ICLC - sinecatechins - Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma - Small Molecules to Inhibit Casein Kinase 1 for Cancer - TG-1042 For more information visit http://www.researchandmarkets.com/research/wnpg9f/basal_cell
BMY: 74.81 (+0.15), NVS: 83.26 (+1.18)
Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), ICPT: 173.03 (+6.13), VBAY: (), GSK: 45.07 (-0.11)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 5.80 (+0.19), INO: 9.88 (+0.26), ADXS: 8.34 (+0.16), GSK: 45.07 (-0.11), NKTR: 17.29 (+1.19), NVS: 83.26 (+1.18)
